Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $77.8 million.

  • Tg Therapeutics' Change in Acquisitions & Divestments fell 1576.38% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.2 million, marking a year-over-year increase of 778.98%. This contributed to the annual value of $310.9 million for FY2024, which is 22308.35% up from last year.
  • As of Q3 2025, Tg Therapeutics' Change in Acquisitions & Divestments stood at $77.8 million, which was down 1576.38% from $49.3 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Acquisitions & Divestments peaked at $92.3 million during Q3 2024, and registered a low of $16.0 million during Q1 2023.
  • Its 4-year average for Change in Acquisitions & Divestments is $52.9 million, with a median of $60.4 million in 2024.
  • Per our database at Business Quant, Tg Therapeutics' Change in Acquisitions & Divestments soared by 35875.62% in 2024 and then plummeted by 3097.81% in 2025.
  • Quarter analysis of 4 years shows Tg Therapeutics' Change in Acquisitions & Divestments stood at $20.3 million in 2022, then rose by 16.81% to $23.7 million in 2023, then skyrocketed by 211.26% to $73.7 million in 2024, then rose by 5.5% to $77.8 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $77.8 million for Q3 2025, versus $49.3 million for Q2 2025 and $80.4 million for Q1 2025.